Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

5 FDA decisions to watch in the fourth quarter of 2026

The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

American Healthcare Must Reward Faster Answers | Opinion

A patient does not wake up hoping for six appointments, three billing departments and a test weeks later. They want an answer.

  • American healthcare focuses on monetizing journey over swift answers.
  • $5.3 trillion spent on healthcare in 2024, with high hospital and physician costs.
  • Incentive structure favors complex diagnoses over quick, accurate patient outcomes.

More from Thursday 1 October →